PR088/#198 EZH2/EZH1 inhibitor tulmimetostat (CPI-0209): preliminary phase II results and first biomarker findings in patients with arid1a-mutant ovarian clear cell or endometrial carcinomas (OCCC/EC)
Year: 2023
Type: article
Study design: Clinical Trial
Authors: Charles Drescher, Harriet Walter, Elvire Pons-Tostivint, Nehal Lakhani, Vincent Ribrag, Martin Gutierrez, Ryan Sullivan, Donald Harvey, Kalyan Banda, Michal Kwiatek, Alejandro Garcia-Sancho, Linda Duska, Pier Luigi Zinzani, Anjali Thakur, Lennart Kann, Rainer Boxhammer, Nicola Faulhaber, Julia Jauch-Lembach, Hedy Kindler
Institutions: Swedish Medical Center, University of Leicester, University Hospitals of Leicester NHS Trust, Centre Hospitalier Universitaire de Nantes, Institut Gustave Roussy, Hackensack University Medical Center, Massachusetts General Hospital, Emory University, Winship Cancer Institute, Fred Hutch Cancer Center, Complejo Hospitalario de Salamanca, Instituto de Investigación Biomédica de Salamanca, University of Virginia, Istituto di Ematologia di Bologna, University of Bologna, MorphoSys (Germany), University of Chicago
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4388495314